Last updated 15 days ago

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

614 patients around the world
Available in Chile, United States, Argentina
Merck Sharp & Dohme LLC
9Research sites
614Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Hospital Británico de Buenos Aires - CABA
Hospital Británico de Buenos Aires - CABA
Recruiting
Perdriel 74, CABA, Buenos Aires
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Av. Crámer 1180, CABA, Buenos Aires
Hospital Alemán
Recruiting
Av. Pueyrredón 1640, CABA, Buenos Aires
Instituto de Oncología de Rosario - IOR
Recruiting
Córdoba 2457, Rosario, Santa Fe
Centro Privado de RMI Río Cuarto
Recruiting
CGI, Pedernera 459, X5800CGI Río Cuarto, Córdoba, Argentina
Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana
Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana
Recruiting
Manzano 343, Recoleta, Región Metropolitana, Santiago
Orlandi Oncología
Recruiting
General Salvo 159, Providencia, Región Metropolitana, Santiago, 7500713
Instituto Oncológico FALP - UIDO
Recruiting
José Manuel Infante 805, Providencia, Región Metropolitana
Clínica Universidad Católica del Maule
Recruiting
Dos Sur 1525, Talca, Maule
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy